Clinical Trials Logo

HER2 Amplified Breast Cancer clinical trials

View clinical trials related to HER2 Amplified Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04366713 Completed - Clinical trials for HER2 Amplified Breast Cancer

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Start date: June 30, 2020
Phase: Phase 2
Study type: Interventional

This study will investigate colon pathology in patients with HER2-positive breast cancer treated with neratinib. Colonoscopy will be performed after eligibility has been confirmed, prior to administration of the first dose of neratinib, and after 28 days of neratinib treatment.